The search for new leadership at BIO presents its board with generational opportunity to redefine the organization to ensure its relevance in a time of tumultuous political, technological and cultural change. The urgency for outside-the-box thinking has never been higher.
When BIO President & CEO Jim Greenwood steps down next fall, the trade association’s board can start by replacing him with two leaders: a scientist or physician or patient who can serve as the public face of BIO’s innovation mission, and someone else who has the experience and skills necessary to influence Congress and the White House.
It is no longer sufficient for BIO CEOs to speak eloquently about cutting-edge science, the path from science to medicine, and the effects of biomedical innovation on individual patients and populations. Every BIO CEO has that capability, or should have it.
What BIO is lacking is a leader who has the credibility to speak as a partner for patients, whose integrity has been established outside the biopharmaceutical industry, and whose